MIR301A

Summary

MIR301A (microRNA 301a, HGNC:31622) is a microRNA gene on chromosome 17q22.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407027 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31622
Approved symbol	MIR301A
Name	microRNA 301a
Location	17q22
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-301, hsa-mir-301a
Ensembl gene	ENSG00000207996
Ensembl biotype	miRNA
OMIM	615675
Entrez	407027
RNAcentral	URS0000759EFA — miRNA, 86 nt, 34 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385261

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385261 — 1 exons

Exon	Start	End
ENSE00001500267	59151136	59151221

Expression profiles

Bgee: expression breadth broad, 74 present calls, max score 75.03.

Top tissues by expression

74 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
kidney	UBERON:0002113	75.03	gold quality
islet of Langerhans	UBERON:0000006	74.88	gold quality
blood	UBERON:0000178	74.84	gold quality
muscle of leg	UBERON:0001383	74.43	gold quality
gastrocnemius	UBERON:0001388	73.98	gold quality
heart left ventricle	UBERON:0002084	72.50	gold quality
fundus of stomach	UBERON:0001160	72.38	gold quality
endometrium	UBERON:0001295	72.18	gold quality
calcaneal tendon	UBERON:0003701	72.09	gold quality
heart	UBERON:0000948	69.62	gold quality
Brodmann (1909) area 9	UBERON:0013540	69.14	gold quality
body of pancreas	UBERON:0001150	68.81	gold quality
granulocyte	CL:0000094	68.53	gold quality
transverse colon	UBERON:0001157	68.09	gold quality
stomach	UBERON:0000945	68.06	gold quality
putamen	UBERON:0001874	67.22	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	67.21	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	67.18	gold quality
tibial artery	UBERON:0007610	66.93	gold quality
lung	UBERON:0002048	66.86	gold quality
amygdala	UBERON:0001876	66.77	gold quality
esophagus mucosa	UBERON:0002469	66.50	gold quality
body of stomach	UBERON:0001161	65.99	gold quality
thoracic aorta	UBERON:0001515	65.70	gold quality
intestine	UBERON:0000160	65.68	gold quality
skin of abdomen	UBERON:0001416	65.43	gold quality
esophagus	UBERON:0001043	65.29	gold quality
small intestine	UBERON:0002108	65.14	gold quality
colon	UBERON:0001155	65.02	gold quality
lower esophagus muscularis layer	UBERON:0035833	64.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.63

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• blocking of miR-301 in A549 cells leads to a decrease in the expression of the host gene, ska2. (PMID:20470754)
• PlGF-induced PAI-1 expression at early time points is post-transcriptionally regulated by two miRNAs, miR-30c and miR-301a. (PMID:21175428)
• MiR-301a is a candidate oncogene that targets the homeobox gene Gax in human hepatocellular carcinoma.The upregulated miR-301a plays an important role in promoting proliferation, migration, and invasion, and in inhibiting apoptosis of HCC cells. (PMID:22373864)
• miR-301a promotes pancreatic cancer progression by repressing Bim. (PMID:22628193)
• miR-301a is involved in cellular clone formation, migration, and invasion in vitro and may play an important role in the clinical progression and prognosis of gastric cancer. (PMID:23832550)
• The expression of miR-301a in UC-MSCs was regulated by TLRs, and miR-301a affected the cytokine secretion of UC-MSCs (PMID:24035358)
• Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/beta-catenin signaling. (PMID:24315818)
• analysis of the molecular network specific to pulmonary hypertension (PH) predicted that the miR-130/301 family is a master regulator of cellular proliferation in PH via regulation of subordinate miRNA pathways with unexpected connections to one another (PMID:24960162)
• Expression of miR-301a was an independent prognostic factor for the survival of patients with triple-negative breast cancer. (PMID:25311065)
• microRNA-130/301 controls vasoconstriction in pulmonary hypertension (PMID:25505270)
• data indicated that miR-301a correlated with the metastatic and invasive ability in human colorectal cancers and miR-301a exerted its role as oncogene by targeting TGFBR2 (PMID:25551793)
• MiR-301a promotes Colorectal cancer progression by directly downregulating SOCS6 expression. (PMID:25591765)
• miR-301a reduced doxorubicin-induced cell apoptosis whereas anti-miR-301a enhanced apoptosis in osteosarcoma (OS) cells, suggesting that up-regulation of miR-301a contributed to chemoresistance of OS cells. (PMID:25727016)
• MiR-301a-3p functions as a novel oncogene in pancreatic ductal adenocarcinoma and the oncogenic activity may involve its inhibition of the target gene SMAD4 (PMID:26019136)
• MicroRNA301 might function as a potential diagnostic biomarker for HCC. (PMID:26191271)
• Data show that increased microRNA miR-301a expression is associated with decreased manganese superoxide dismutase (MnSOD) expression in pancreatic ductal adenocarcinoma (PDAC) specimens. (PMID:26384137)
• miR-301a promotes pancreatic cancer growth by affecting MnSOD levels. (PMID:26384137)
• we show that fenofibrate, a PPAR-alpha agonist, increased the expression of miR-301a/miR-454 and SKA2 in human microvascular endothelial cell line (HMEC) cells; the former were responsible for reduced expression of ET-1 and PAI-1 (PMID:26460070)
• MiR-301a promotes cell proliferation and inhibits apoptosis by direct targeting TIMP2 in multiple myeloma (PMID:26464662)
• A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions (PMID:26667495)
• the data indicated that miR-301a-3p and Th17 cells were augmented in peripheral blood, which may play an important role in the process of Rheumatoid arthritis. (PMID:26782362)
• miR-301a/b-NDRG2 might be an important axis modulating autophagy and viability of prostate cancer cells under hypoxia. (PMID:26813459)
• Our results suggest that CNVs of miR-146a, miR-23a and miR-301a confer susceptibility to VKH syndrome, but not to BD. The contribution of miR-23a to VKH syndrome may be mediated by increasing the production of IL-6. (PMID:26818976)
• Results provided evidence that the expression levels of miR-301a in Ewing’s sarcoma (ES) cells were significantly increased and inversely correlated with PTEN expression levels, and that miR-301a played important roles in ES cell proliferation and tumorigenesis by targeting PTEN mRNA. (PMID:26846737)
• Loss of miR301 expression is associated with breast cancer. (PMID:26967567)
• data indicate that microRNA-301a functions as an oncogene in prostate cancer by directly targeting the p63 tumor suppressor leading to loss of E-cadherin and epithelial-mesenchymal transition (PMID:26990571)
• High miR301a expression is associated with glioma cell invasion. (PMID:27006177)
• Overexpressed miR-301a may increase CDC14A expression and promote cell proliferation and migration in osteosarcoma cells. Therefore, miR- 301a may be useful for osteosarcoma diagnosis and therapy. (PMID:27323075)
• MiR-301a and miR-301b are 2 hypoxia-responsive miRNAs that decrease autophagy of prostate cancer cells in hypoxia by targeting NDRG2. Through downregulating NDRG2, miR-301a and miR-301b can promote radioresistance of prostate cancer cells. (PMID:27327120)
• miR-301a may represent a novel prognostic indicator, a biomarker for the early detection of lymph node metastasis and a therapeutic target in NSCLC. (PMID:27461635)
• Among these miRNAs, only miR-181b-5p, miR-195-5p and miR-301a-3p expressions were found to be significantly different between the treatment-resistant group and the group responding well to the treatment. miRNAs may cause resistance by silencing the receptor genes of the drugs used for schizophrenia treatment. miR-181b-5p, miR-195-5p and miR-301a-3p may be candidate indicators (PMID:27552670)
• miR-301a may be used as a potential therapeutic target in the treatment of human malignant melanoma. (PMID:27855389)
• Low miR301-a expression is associated with chronic myelogenous leukemia. (PMID:28035415)
• In summary, we demonstrated that MIR301A expression was significantly increased in the IEC of patients with active IBD and CRC. MIR301A induced production of several proinflammatory cytokines (eg, IL1b, IL6, IL8, and TNF) by IEC and compromised intestinal barrier through inhibiting BTG1, which was significantly decreased in colonic mucosa of patients with active CD and UC. (PMID:28193514)
• Data show that the Japanese encephalitis virus (JEV)-induced expression of miR-301a led to inhibition of the production of the transcription factor IFN regulatory factor 1 (IRF1) and the signaling protein suppressor of cytokine signaling 5 (SOCS5). (PMID:28196914)
• anti-miR-301a-5p significantly blocked vancomycin-induced apoptosis and caspase activity in HK-2 cells, which was accompanied by downregulation of p53, and upregulation of MITF, HDGF and MDM-4 together. (PMID:29022913)
• Serum exosomal miR-301a expression may serve as a novel biomarker for glioma diagnosis and as a prognostic factor for advanced grade disease. (PMID:29076027)
• Data show that miR-301a suppressed the expression of cyclin-dependent kinase inhibitor p21 (p21) and Smad4 protein, and subsequently promoted G1/S cell cycle transition and cell proliferation in vitro and xenograft growth in nude mice in vivo. (PMID:29331421)
• These results suggest that analysing miR-301a expression in the breast tissue biopsy specimen at the time of diagnosis could have the potential to identify patients who are at high risk for developing metastasis as well as patients who might be candidates for active surveillance. (PMID:29396508)
• MiR-301a suppression abolished the protective functions of RP11-445H22.4 silencing on LPS-treated ATGC5 cells. (PMID:29414810)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	dre-mir-301a-1	ENSDARG00000083420
rattus_norvegicus	Mir301a	ENSRNOG00000035586

Paralogs (2): MIR130A (ENSG00000208009), MIR301B (ENSG00000212102)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.